Source: Seeking Alpha
Eli Lilly and Co (NYSE:LLY)
Q2 2014 Results Earnings Conference Call
July 24, 2014, 09:00 am ET
Executives
John Lechleiter – Chairman of the Board, President, Chief Executive Officer
Phil Johnson – Vice President, Investor Relations
Derica Rice – Chief Financial Officer, Executive Vice President – Global Services
Enrique Conterno – Senior Vice President and President – Lilly Diabetes
Dave Ricks – Senior Vice President and President, Lilly Bio-Medicines
Jan Lundberg – Executive Vice President – Science and Technology, President – Lilly Research Laboratories
Sue Mahony – Senior Vice President and President – Lilly Oncology
Ilissa Rassner, Director, Investor Relations
Analysts
Tim Anderson – Sanford Bernstein
Mark Schoenebaum – ISI Group
Jamie Rubin – Goldman Sachs
John Boris – SunTrust
Chris Schott – JPMorgan
Seamus Fernandez – Leerink
Steve Scala – Cowen
Vamil Divan – Credit Suisse
Colin Bristow – Bank of America Merrill Lynch
Jeff Holford – Jefferies
Alex Arfaei – BMO Capital Markets
Marc Goodman – UBS
Damien Conover – MorningStar
Gregg Gilbert – Deutsche Bank
Mark Purcell – Barclays
Operator
Ladies and gentlemen, thank you for standing by. Welcome to the Q 2014 earnings call. At this time, all participants are in a listen only mode. Later we will conduct a question-and-answer session. (Operator Instructions). As a reminder, this conference is being recorded.
I would now like to turn the conference over to our host, Chairman, President and CEO, Dr. John Lechleiter. Please go ahead.
John Lechleiter – Chairman of the Board, President, Chief Executive Officer
Thank you. Good morning, everyone. Thanks for joining us today to discuss Eli Lilly and Company’s second quarter 2014 earnings. As the operators said, I am John Lechleiter, Lilly’s Chairman, President and CEO.
Similar to our last call, this morning we are bringing more of our senior leaders into the room here to participate and to answer your questions and we hope that this enhances the quality of the information we provide you during these sessions. Joining me on today’s call are Derica Rice, our Chief Financial Officer, Dr. Jan Lundberg, our President of Lilly Research Laboratories, Sue Mahony, President of Lilly Oncology, Enrique Conterno, President of Lilly diabetes, Dave Ricks, President of Lilly Bio-Medicines, Chito Zulueta, President of Emerging Markets, Jeff Simmons, President of Elanco Animal Health and Ilissa Rassner, Brad Robling and Phil Johnson of Lilly’s Investor Relations team.
Pages: First |1 | ... | Next → | Last | View Full Transcript